Artificial Intelligence
KPMG announces strong FY19 global revenue growth
KPMG today announced record revenues of $29.75 billion for the fiscal year ending 30 September 2019 (FY19), representing a 6.2% increase in local currency terms on FY18.
- Revenue growth driven by solid FY19 performance across all KPMG regions, with Asia Pacific delivering the fastest growth of 9.3% driven by 14.1% growth in Advisory. Americas region growing at 6.6% and in Europe, Middle East and Africa, including India (EMA) by 4.7%.
- Advisory growing at 7.9% contributed the largest proportion of the increase in total revenues, supported by double-digit growth in deal related services and digital transformation solutions.
- Audit grew by 3.7% while Tax & Legal Services grew by 7.8%.
- Consistently positive growth across each of KPMG’s five industry sectors, Financial Services 3.9%, Industrial Markets 4.5%, Consumer Markets 4.5%, with Technology Media & Telecoms 8.1% and Infrastructure Government & Healthcare 10.8% being particular highlights.
- Our position as a leading employer of choice reinforced with total headcount increasing to more than 219,000 people across 147 countries and territories.
- KPMG is focused on building an inclusive and diverse culture, and has increased female diversity among our leadership ranks to 25% of Partners and Directors, while over 30% of new partners promoted and recruited in our largest practices were female.
- KPMG people volunteered approximately 550,000 hours of time in the past twelve months, including 100,000 hours of pro-bono professional services.
“We are pleased to have achieved strong growth during an important transitional year for KPMG as we focus on making significant investments as part of our multi-year collective strategy implementation,” said Bill Thomas, Global Chairman and CEO, KPMG International.
“In addition to our enduring focus on quality and trust we’re also enhancing our leadership position in the digital transformation of professional services through an expected investment of $5 billion in innovation, people and technology over the coming five years. This will accelerate the digital transformation of KPMG and enable us to better serve clients as they continue to address their own transformations.”
Audit, Tax and Advisory
Audit
Audit revenues for the year grew globally by 3.7% to $11.18 billion.
KPMG is committed to improving quality and consistency by investing in game-changing methodologies and technology innovations. During 2019 KPMG continued the roll out of Clara, KPMG’s smart audit platform which brings KPMG’s powerful data and analytics capabilities into one interface, allowing our professionals to work smarter while interacting with clients online in real time as they conduct the audit. KPMG Clara has been deployed in more than 100 countries and territories to date.
As part of the network’s collective strategy all KPMG firms are committed to driving tangible and sustainable advances in quality and consistency. As a global organization, KPMG is driving the use of centralization to achieve the consistency regulators and stakeholders expect and deserve.
“As an organization we are making unprecedented investments to advance audit quality in a hyper-competitive global audit marketplace our priority continues to be on aligning top talent with next generation technology to deliver stakeholder value and build trust,” said Bill O’Mara, Global Head of Audit, KPMG International.
Tax & Legal Services
Tax & Legal Services revenues grew 7.8% in FY19 to $6.62 billion up from 6.3% growth in FY18, driven by strong demand for KPMG’s multi-disciplinary tax services, including Corporate and Business Tax compliance which continued to be enhanced by ongoing collective investments. Strong growth in Legal Services has been supported by the continuing expansion of coverage of the offering across KPMG.
With the introduction of new technologies and enhanced service offerings, KPMG has been able to help tax and legal leaders not only meet compliance obligations but also transform their departments and establish new ways of working through such initiatives as Tax Reimagined, KPMG’s unique framework that combines the strengths of our technology, transformation and compliance capabilities.
“As organizations face unprecedented regulatory change and challenging geopolitical shifts, as well as the impacts of digitalization and heightened public attention on tax and legal activities, our collective investments in the depth, breadth and connectivity of our multidisciplinary tax and legal services paved the way for growth in these areas through FY19,” said Jane McCormick, Global Head of Tax & Legal Services, KPMG International.
Advisory
Advisory grew by 7.9% in FY19 to $11.95 billion, driven in part by high client demand for strategy, deal related services and digital transformation solutions.
“As our clients shape, transform and protect their businesses to maintain a competitive edge in an increasingly digital world, they are looking to KPMG’s capabilities and globally minded practitioners to help them address these critical challenges and opportunities. KPMG’s deep industry expertise, a future focused view of sectors and business models and our strong tools, methods and technologies help clients hone their strategies, align their operations across the enterprise, and become more customer centric. These demands have set the stage for our strong overall growth,” said Mark A. Goodburn, Global Head of Advisory, KPMG International.
KPMG’s Advisory capabilities continue to be recognized by the analyst community. In 2019, KPMG was ranked as a Leader in 25 major evaluations in areas central to our client’s transformation agendas including cybersecurity and artificial intelligence, digital change management, and corporate services as well as our Powered Enterprise and Connected Enterprise solutions.
Notes to editors:
KPMG FY19 member firm revenues (US$ billions)
|
Regions |
Current |
Prior |
Local Growth (%) |
US$ Growth (%) |
|
Americas |
11.72 |
11.10 |
6.6% |
5.6% |
|
Asia Pacific |
5.14 |
4.88 |
9.3% |
5.3% |
|
EMA |
12.89 |
12.98 |
4.7% |
(0.7%) |
|
Total |
29.75 |
28.96 |
6.2% |
2.7% |
|
Functions |
Current |
Prior |
Local Growth (%) |
US$ Growth (%) |
|
Audit |
11.18 |
11.15 |
3.7% |
0.3% |
|
Tax |
6.62 |
6.34 |
7.8% |
4.4% |
|
Advisory |
11.95 |
11.47 |
7.9% |
4.2% |
|
Total |
29.75 |
28.96 |
6.2% |
2.7% |
All figures throughout this press release are in US dollars. All growth figures are in local currency except where noted.
FY19 and FY18 revenues, reported in USD billions, are translated at the average exchange rates prevailing in each respective financial year.
The industry analysis excludes revenues reported outside of KPMG’s standard sector taxonomy. Prior year figures have been restated to reflect FY18 sector reclassifications.
Local growth percentages are based on maintaining consistent FY19 exchange rates across both FY19 and FY18.
Legal services may not be offered to SEC registrant audit clients or where otherwise prohibited by law.
The following global reports have also been issued by KPMG International today:
KPMG’s 2019 Global Review reflects on our record of achievement over the past year, demonstrating the insights and expertise of KPMG professionals and the unrelenting focus on acting with integrity and quality in everything we do.
KPMG’s 2019 International Transparency Report provides insights and details on how we continually strive to enhance audit quality, which is a direct reflection of the KPMG network’s unwavering commitment to audit quality, an integral element of our business and culture.
SOURCE KPMG International
STOCKHOLM, April 19, 2024 /PRNewswire/ — On 5 April 2024, SciBase Holding AB (publ) (“SciBase” or the “Company”) announced that the Board of Directors, with the support of the authorization granted by the annual general meeting held on 17 May 2023, had resolved on a rights issue of units, consisting of new shares and warrants of series TO 2, of approximately SEK 15 million (the “Rights Issue). Today, SciBase announces that the prospectus relating to the Rights Issue (the “Prospectus”) has been approved by the Swedish Financial Supervisory Authority (the “SFSA”) and has been made available on the Company’s webpage, https://investors.scibase.se/en/share/prospectus-regarding-shares, together with other information related to the Rights Issue. The Prospectus will also be made available on Vator Securities’ webpage, www.vatorsecurities.se , and at the SFAS’s webpage, www.fi.se.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.
Timetable for the Rights Issue
19 April 2024
Record date to receive unit rights
23 April 2024 – 2 May 2024
Trading in unit rights
23 April 2024 – 7 May 2024
Subscription period
23 April 2024 – 27 May 2024
Trading in BTU
Around 10 May 2024
Announcement of the outcome of the Rights Issue
3 April 2029 – 17 April 2029
Subscription period for warrants of series TO 2
Advisors
Vator Securities is the financial advisor and Advokatfirman Schjødt is the legal advisor to SciBase in connection with the Rights Issue.
For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA)Vator SecuritiesTel: +46 8 580 065 99Email: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The Company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
Important information
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Any acquisition of units in SciBase in the Rights Issue should only be made on the basis of the information contained in the formal prospectus issued in connection with the Rights Issue, which was approved by the Swedish Financial Supervisory Authority on 19 April 2024.
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“Securities Act”) and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
This press release contains forward-looking statements related to the Company’s intentions, estimates or expectations with regard to the Company’s future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “implies,” “should,” “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue,c3964524
The following files are available for download:
https://mb.cision.com/Main/12371/3964524/2745667.pdf
Publishing of prospectus SciBase
View original content:https://www.prnewswire.co.uk/news-releases/scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue-302122089.html
Artificial Intelligence
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 – Exclusive Report by 360iResearch
PUNE, India, April 18, 2024 /PRNewswire/ — The report titled “Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $342.20 million in 2023 to reach $832.56 million by 2030, at a CAGR of 13.54% over the forecast period.
“The Global Surge in Adoption of Matching Software for Enhanced Participant Enrollment”
Clinical trials matching software stands at the forefront of revolutionizing clinical research by automating the process of identifying and enrolling eligible participants. These platforms offer a streamlined approach to match patient health profiles with trial requirements, accelerating enrollment and supporting the shift toward personalized healthcare using these advanced AI and ML technologies. Although integrating these systems poses challenges due to variations in healthcare IT infrastructure and the imperative for rigorous data security, the potential for market growth is substantial. In the Americas, a robust clinical trials ecosystem thrives; in the European Union, it has unified regulatory standards and extended to emerging regions such as the Middle East, Africa, and the APAC countries; the demand for such innovative solutions is on a steep rise. This demand is fueled by governmental support, the evolving regulatory landscape, and strategic partnerships to embed these solutions within electronic health records, underscoring a global movement toward optimizing clinical trial processes to better cater to specific patient demographics.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“The Rise of Virtual Trials and Advanced Matching Software”
The healthcare landscape is witnessing a transformative shift toward virtual clinical trials, fueled by technological advancements and the necessity for continuity during the COVID-19 pandemic. This transition supports research amid social distancing measures and introduces significant cost savings by reducing the need for physical infrastructure and in-person interactions. The efficiencies brought by electronic health records (EHR), wearable technologies, and automation streamline the entire process, from patient recruitment to data analysis. Several approaches, endorsed by regulatory bodies such as the FDA, represent a leap forward in making clinical trials more accessible and streamlined, ensuring that more patients can participate in potentially life-saving research without the geographical and logistic constraints of traditional trials.
“Enhancing Clinical Trials through Advanced Analytics, Rigorous Compliance, and Precision-Patient Matching”
Integrating advanced analytics, meticulous compliance monitoring, and precision-patient matching marks a significant advancement toward maximizing efficiency and fostering trial diversity. The software delivers insightful data on trial progress, participant demographics, and enrollment figures, empowering stakeholders to make well-informed decisions and optimize resource distribution to meet trial goals effectively by implementing cutting-edge analytics. The built-in compliance feature ensures trials are conducted in strict adherence to regulatory standards, minimizing risks associated with non-compliance. Furthermore, a robust data management system guarantees the integrity and availability of clinical trial data, which is critical for the seamless operation and real-time analysis of trials. The software includes state-of-the-art patient matching technology, which employs sophisticated algorithms and artificial intelligence to expedite recruitment by accurately identifying candidates who match specific trial requirements. This innovative approach accelerates the recruitment timeline and enhances the diversification of trial participants, paving the way for more inclusive and representative clinical research outcomes.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Medidata by Dassault Systèmes SE at the Forefront of Clinical Trials Matching Software Market with a Strong 11.30% Market Share”
The key players in the Clinical Trials Matching Software Market include International Business Machines Corporation, Science 37, Inc. by eMed, LLC, Medidata by Dassault Systèmes SE, AutoCruitment LLC, Deep 6 AI Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trials Matching Software Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trials Matching Software Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trials Matching Software Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Dive into the Clinical Trials Matching Software Market Landscape: Explore 190 Pages of Insights, 286 Tables, and 22 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trials Matching Software Market, by FunctionalityClinical Trials Matching Software Market, by DeploymentClinical Trials Matching Software Market, by End-UseAmericas Clinical Trials Matching Software MarketAsia-Pacific Clinical Trials Matching Software MarketEurope, Middle East & Africa Clinical Trials Matching Software MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030Virtual Clinical Trials Market – Global Forecast 2024-2030Clinical Trials Management System Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo – https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clinical-trials-matching-software-market-projected-to-reach-832-56-million-by-2030—exclusive-report-by-360iresearch-302119709.html
BOSTON, April 18, 2024 /PRNewswire/ — The RepTrak™ Company, the world’s leading reputation data and insights company, released its annual Global RepTrak 100 report. Utilizing its advanced reputation monitoring software, RepTrak gathered data from more than 243,000 survey responses across 14 major economies to rank the world’s 100 most reputable companies. They share that ranking alongside a full analysis of global corporate reputation trends and corresponding public sentiment in the 2024 report.
After two years of consecutive Reputation Score declines, this year’s Score is back up with an increase from 73.2 in 2023 to 73.8 in 2024. It’s a small increase after 2023’s full one-point drop. However, it’s an encouraging sign that companies have begun to recover from reputation falls driven by many challenges: macroeconomic issues, workplace difficulties, product problems, and corporate responsibility skepticism.
“This year’s report underscores a pivotal shift in the corporate landscape, spotlighting the remarkable adaptability and dedication of the Top 100 companies in responding to the dynamic needs of stakeholders,” states RepTrak CEO Mark Sonders. “The companies featured in our report are not just riding the wave of change; they are the ones steering it, proving that the best approach to business is one that embraces evolution and champions progress.”
RepTrak’s report explores how people thought, felt, and acted toward companies over the past year. Findings include notable increases in Conduct and Citizenship efforts, stakeholders’ rising willingness to invest, culturally resonant brand communications, and ESG Scores that soared despite skepticism around the acronym.
To read the full 2024 Global RepTrak 100 report, please visit: www.reptrak.com/globalreptrak
About RepTrak
The RepTrak™ Company is the world’s leading reputation data and insights company. We help companies by organizing and grading a variety of reputational elements, offering a real-world report card on their corporate reputation. Subscribers to the RepTrak program use our predictive insights to protect business value, improve return on investment, and increase their positive impact on society. RepTrak’s pairing of advanced metrics and dedicated reputation advisors offers clients an actionable analysis of their reputation data, aligning business objectives with stakeholder sentiment across different markets and sectors.
Established in 2004, The RepTrak Company owns the world’s largest reputation benchmarking database, gathering over 1 million company ratings per year used by CEOs, boards, and executives in more than 60 countries worldwide. For more information, please visit: www.reptrak.com
Logo – https://mma.prnewswire.com/media/2391550/RepTrak_Logo_Logo.jpg
Photo – https://mma.prnewswire.com/media/2391551/2024_GRT_Spreads__Instagram_Post.jpg
View original content:https://www.prnewswire.co.uk/news-releases/reptrak-announces-2024-global-reptrak-100-report-302121513.html
-
Artificial Intelligence7 days agoIn-Depth Analysis of Germany and France Data Center Markets: Germany Poised to Contribute Over $12.24 Billion Opportunities in the Next 6 Years – Arizton
-
Artificial Intelligence7 days agoCogX Festival Set to Debut in Los Angeles at Century Plaza on May 7th, 2024
-
Artificial Intelligence5 days agoSilent Eight secures AIA as its latest client
-
Artificial Intelligence4 days agoGlobal Networking Innovator Huawei Leads the New Era of Campus Network Technology
-
Artificial Intelligence2 days agoHuawei Introduces AI Technologies to Accelerate Network Transformation Towards All Intelligence in the Net5.5G Era
-
Artificial Intelligence4 days agoBroadcom Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Delivering Reliable and Flexible Hybrid Cloud Management Solutions
-
Artificial Intelligence4 days agoAI Chips and Chat GPT – IDTechEx Explores AI and Robotics
-
Artificial Intelligence4 days agoGFT teams up with Google Cloud to launch ‘GenAI Intelligent Assistant’
